1. Scrip
  2. >>Focus On Asia
  3. >>China

Hengrui, BeyondSpring In Arbitration Face-Off After Cancer Deal Setbacks

 
• By Dexter Jie Yan

A Chinese court decision sheds light on how Chinese major Hengrui Medicine is seeking to reduce or avoid potential losses worth up to $27m following regulatory setbacks with the tubulin inhibitor plinabulin, in-licensed from BeyondSpring in 2021.

Jiangsu Hengrui Medicine Co., Ltd. is apparently going all-in to salvage a CNY200m ($27m) upfront payment it made to Dalian Wanchunbulin Pharmaceuticals, a China-based subsidiary of BeyondSpring Inc., in a licensing deal for an oncology product sealed in 2021.

Earlier this year, the two companies went to arbitration at the China International Economic and Trade Arbitration Commission (CIETAC), according...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

Chinese Biotechs Bet On FDA-Cleared Phase III Trials With First-Mover Potential

 
• By Dexter Jie Yan

Ascentage and Biokin are the latest novel drug players from China to progress potential first-in-class molecules into Phase III trials in the US. Meanwhile, Zai Lab is seeking US accelerated approval for its lung cancer candidate.

China-Originated Assets Lead Global GLP-1 Deals

 
• By Xu Hu

The total value of deals for GLP-1-associated assets so far this year is already double that of the previous two years combined, with China-originated molecules accounting for a substantial majority. Scrip takes a look at some of the key factors behind this activity.

China’s BRL Gears Up For First UCAR-T Trial In Leukemia/Lymphoma

 
• By Xu Hu

Shanghai-based BRL Medicine is building a novel pipeline led by universal CAR-Ts. Its founder talks to Scrip about the benefits of this approach, China's potential advantages in the field and challenges faced by new ventures.

BeBetter, Trinomab Advance IPOs On China’s STAR Market In Firsts Since Policy Easing

 
• By Dexter Jie Yan

BeBetter becomes first unprofitable innovative drug maker to have application for an IPO on Shanghai's STAR Market cleared by China’s top securities regulator, while Trinomab becomes first among peers to have IPO filing accepted.

More from Focus On Asia

Chinese Biotechs Bet On FDA-Cleared Phase III Trials With First-Mover Potential

 
• By Dexter Jie Yan

Ascentage and Biokin are the latest novel drug players from China to progress potential first-in-class molecules into Phase III trials in the US. Meanwhile, Zai Lab is seeking US accelerated approval for its lung cancer candidate.

Glenmark Fortifying Branded Play, Shifts Focus To High Margin Products

 
• By Anju Ghangurde

Glenmark signals thrust on high margin products, while exiting tail end brands as part of efforts to emerge as a branded company. In-licensed assets like Brukinsa and Tevimbra are seen as pivotal to driving growth alongside.

China-Originated Assets Lead Global GLP-1 Deals

 
• By Xu Hu

The total value of deals for GLP-1-associated assets so far this year is already double that of the previous two years combined, with China-originated molecules accounting for a substantial majority. Scrip takes a look at some of the key factors behind this activity.